サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1675282

うつ病治療薬市場：薬剤クラス別、疾患タイプ別、薬剤タイプ別、流通チャネル別、地域別、2025-2033年

Depression Drugs Market Report by Drug Class, Disorder Type, Drug Type, Distribution Channel, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 148 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
うつ病治療薬市場：薬剤クラス別、疾患タイプ別、薬剤タイプ別、流通チャネル別、地域別、2025-2033年
出版日: 2025年03月01日
発行: IMARC
ページ情報: 英文 148 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

うつ病治療薬市場の世界市場規模は2024年に192億米ドルに達しました。IMARC Groupは、2025年から2033年にかけての成長率（CAGR）は2.9％で、2033年には251億米ドルに達すると予測しています。座りっぱなしのライフスタイルやストレスが原因で大衆の間でうつ病の症例が増加していること、薬剤の製剤化とデリバリー技術の進歩が進んでいること、モバイルアプリやオンライン治療プラットフォームなどのデジタル治療への嗜好が高まっていることなどが、市場成長を促す要因となっています。

うつ病は、ポジティブな感情の欠如、常に低い気分、多数の認知的、身体的、行動的、感情的症状を特徴とする精神障害です。症状を特定し、患者の病歴をチェックすることで診断されます。その後、うつ病治療薬を用いて治療します。うつ病治療薬は、脳内のセロトニンなどの神経伝達物質の働きのバランスをとり、患者の気分や感情をコントロールします。これらの薬剤は、不安、季節性感情障害、ジスティミアの兆候を緩和するのに役立ちます。

世界保健機関（WHO）によると、うつ病は身体障害の主な原因のひとつであり、世界中で2億6,400万人以上が影響を受けています。社会不安やうつ病などの精神障害の有病率の増加は、うつ病治療薬市場の成長を促進する重要な要因の1つです。さらに、各国政府が完全な閉鎖を課し、社会的距離を置く手段の採用を推進しているため、人口のかなりの部分の日常生活が変化し、その結果、個人のメンタルヘルスに悪影響を及ぼしています。この動向は、うつ病治療薬の売上を押し上げるもう一つの大きな成長要因として浮上しています。さらに、副作用が少なく長期的な効果が期待できる抗うつ薬の開発における新しい技術の出現は、新薬の受け入れの増加と相まって、今後数年間の市場の成長を促進すると予想されます。

IMARC Group社の最新レポートでは、世界のうつ病治療薬市場についてあらゆる重要な側面から深く考察しています。その内容は、市場のマクロな概要から、業界実績のミクロな詳細、最近の動向、主要市場促進要因・課題、SWOT分析、ポーターのファイブフォース分析、バリューチェーン分析など多岐にわたります。本レポートは、業界関係者、投資家、研究者、コンサルタント、ビジネス戦略家、および何らかの形でうつ病治療薬市場に関わる、または参入を計画しているすべての方々にとって必読の内容となっています。

本レポートで扱う主な質問

  • うつ病治療薬市場の世界市場規模は？
  • COVID-19は世界のうつ病治療薬市場にどのような影響を与えているか？
  • 世界のうつ病治療薬市場の期待成長率は？
  • 世界のうつ病治療薬市場を牽引する主な要因は何か？
  • 世界のうつ病治療薬市場の疾患タイプ別内訳は？
  • 世界のうつ病治療薬市場の流通チャネル別内訳は？
  • うつ病治療薬市場の世界における主要地域は？
  • 世界のうつ病治療薬市場における主要企業／プレーヤーは？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界のうつ病治療薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場内訳：薬剤クラス別
  • 市場内訳：疾患タイプ別
  • 市場内訳：薬剤タイプ別
  • 市場内訳：流通チャネル別
  • 市場内訳：地域別
  • 市場予測

第6章 市場内訳：薬剤クラス別

  • 非定型抗精神病薬
  • セロトニン・ノルエピネフリン再取り込み阻害剤（SNRI）
  • 選択的セロトニン再取り込み阻害薬（SSRI）
  • 中枢神経系刺激薬
  • 三環系抗うつ薬
  • モノアミン酸化酵素阻害剤
  • その他

第7章 市場内訳：疾患タイプ別

  • 大うつ病性障害
  • 強迫性障害
  • 全般性不安障害
  • パニック障害
  • その他

第8章 市場内訳：薬剤タイプ別

  • ジェネリック医薬品
  • ブランド医薬品

第9章 市場内訳：流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他

第10章 市場内訳：地域別

  • 北米
  • 欧州
  • アジア太平洋地域
  • 中東・アフリカ
  • ラテンアメリカ

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Otsuka Pharmaceutical
    • Pfizer
    • Eli Lilly and Company
    • AstraZeneca
    • Novartis
    • Bristol-Myers Squibb
    • GlaxoSmithKline
    • Takeda Pharmaceutical Company
    • Allergan
    • Johnson & Johnson
    • Zhejiang NHU Company Ltd
    • Sebela Pharmaceuticals
図表

List of Figures

  • Figure 1: Global: Depression Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Depression Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Depression Drugs Market: Breakup by Drug Class (in %), 2024
  • Figure 4: Global: Depression Drugs Market: Breakup by Disorder Type (in %), 2024
  • Figure 5: Global: Depression Drugs Market: Breakup by Drug Type (in %), 2024
  • Figure 6: Global: Depression Drugs Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Depression Drugs Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Depression Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 9: Global: Depression Drugs Industry: SWOT Analysis
  • Figure 10: Global: Depression Drugs Industry: Value Chain Analysis
  • Figure 11: Global: Depression Drugs Industry: Porter's Five Forces Analysis
  • Figure 12: Global: Depression Drugs (Atypical Antipsychotics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Depression Drugs (Atypical Antipsychotics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Depression Drugs (Serotonin-Norepinephrine Reuptake Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Depression Drugs (Serotonin-Norepinephrine Reuptake Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Depression Drugs (Selective Serotonin Reuptake Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Depression Drugs (Selective Serotonin Reuptake Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Depression Drugs (Central Nervous System (CNS) Stimulants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Depression Drugs (Central Nervous System (CNS) Stimulants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Depression Drugs (Tricyclic Antidepressants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Depression Drugs (Tricyclic Antidepressants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Depression Drugs (Monoamine Oxidase Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Depression Drugs (Monoamine Oxidase Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Depression Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Depression Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Depression Drugs (Major Depressive Disorder) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Depression Drugs (Major Depressive Disorder) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Depression Drugs (Obsessive-Compulsive Disorder) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Depression Drugs (Obsessive-Compulsive Disorder) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Depression Drugs (Generalized Anxiety Disorder) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Depression Drugs (Generalized Anxiety Disorder) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Depression Drugs (Panic Disorder) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Depression Drugs (Panic Disorder) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Depression Drugs (Other Disorder Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Depression Drugs (Other Disorder Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Global: Depression Drugs (Generic Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Global: Depression Drugs (Generic Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Global: Depression Drugs (Branded Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Global: Depression Drugs (Branded Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Global: Depression Drugs Market: Sales through Hospital Pharmacies (in Million USD), 2019 & 2024
  • Figure 41: Global: Depression Drugs Market Forecast: Sales through Hospital Pharmacies (in Million USD), 2025-2033
  • Figure 42: Global: Depression Drugs Market: Sales through Retail Pharmacies (in Million USD), 2019 & 2024
  • Figure 43: Global: Depression Drugs Market Forecast: Sales through Retail Pharmacies (in Million USD), 2025-2033
  • Figure 44: Global: Depression Drugs Market: Sales through Online Pharmacies (in Million USD), 2019 & 2024
  • Figure 45: Global: Depression Drugs Market Forecast: Sales through Online Pharmacies (in Million USD), 2025-2033
  • Figure 46: Global: Depression Drugs Market: Sales through Other Distribution Channels (in Million USD), 2019 & 2024
  • Figure 47: Global: Depression Drugs Market Forecast: Sales through Other Distribution Channels (in Million USD), 2025-2033
  • Figure 48: North America: Depression Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: North America: Depression Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Europe: Depression Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Europe: Depression Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Asia Pacific: Depression Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Asia Pacific: Depression Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Middle East and Africa: Depression Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Middle East and Africa: Depression Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Latin America: Depression Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Latin America: Depression Drugs Market Forecast: Sales Value (in Million USD), 2025-2033

List of Tables

  • Table 1: Global: Depression Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Depression Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 3: Global: Depression Drugs Market Forecast: Breakup by Disorder Type (in Million USD), 2025-2033
  • Table 4: Global: Depression Drugs Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 5: Global: Depression Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 6: Global: Depression Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Depression Drugs Market Structure
  • Table 8: Global: Depression Drugs Market: Key Players
目次
Product Code: SR112025A1563

The global depression drugs market size reached USD 19.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 25.1 Billion by 2033, exhibiting a growth rate (CAGR) of 2.9% during 2025-2033. The growing cases of depression among the masses due to sedentary lifestyle and stress, increasing advancements in drug formulation and delivery techniques, and rising preferences for digital therapeutics, such as mobile apps and online therapy platforms, are some of the factors impelling the market growth.

Depression is a mental disorder characterized by the absence of positive emotions, constant low mood and numerous cognitive, physical, behavioral and emotional symptoms. It is diagnosed by identifying the symptoms and checking the medical history of the patient. It is then treated using depression drugs, which balance the functioning of neurotransmitters, such as serotonin, in the brain and controlling the mood and emotions of the patient. These drugs can assist in relieving the signs of anxiety, seasonal affective disorder and dysthymia.

According to the World Health Organization (WHO), depression is one of the leading causes of disability and has impacted more than 264 million people across the globe. The increasing prevalence of mental disorders, such as social anxiety and depression, represents one of the key factors propelling the depression drugs market growth. Moreover, as governments of various countries have imposed complete lockdown and are promoting the adoption of social distancing measures, the everyday routine of a significant portion of the population has been altered, which, in turn, has negatively impacted the mental health of individuals. This trend has emerged as another major growth-inducing factor boosting the sales of depression drugs. Furthermore, the emergence of novel techniques for the development of antidepressants with minimal side-effects and long-term results, in confluence with the increasing acceptance of new medications, is anticipated to impel the market growth in the upcoming years.

IMARC Group's latest report provides a deep insight into the global depression drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the depression drugs market in any manner.

Key Market Segmentation:

Breakup by Drug Class:

  • Atypical Antipsychotics
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Central Nervous System (CNS) Stimulants
  • Tricyclic Antidepressants
  • Monoamine Oxidase Inhibitors
  • Others

Breakup by Disorder Type:

  • Major Depressive Disorder
  • Obsessive-Compulsive Disorder
  • Generalized Anxiety Disorder
  • Panic Disorder
  • Others

Breakup by Drug Type:

  • Generic Drugs
  • Branded Drugs

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Breakup by Region:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

Competitive Landscape:

The report has also analyzed the competitive landscape of the market with some of the key players being Otsuka Pharmaceutical, Pfizer, Eli Lilly and Company, AstraZeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical Company, Allergan, Johnson & Johnson, Zhejiang NHU Company Ltd, Sebela Pharmaceuticals, etc.

Key Questions Answered in This Report

  • 1.What is the size of the global depression drugs market?
  • 2.What has been the impact of COVID-19 on the global depression drugs market?
  • 3.What is the expected growth rate of the global depression drugs market?
  • 4.What are the key factors driving the global depression drugs market?
  • 5.What is the breakup of the global depression drugs market based on the disorder type?
  • 6.What is the breakup of the global depression drugs market based on the distribution channel?
  • 7.What are the key regions in the global depression drugs market?
  • 8.Who are the key companies/players in the global depression drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Depression Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Drug Class
  • 5.5 Market Breakup by Disorder Type
  • 5.6 Market Breakup by Drug Type
  • 5.7 Market Breakup by Distribution Channel
  • 5.8 Market Breakup by Region
  • 5.9 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Atypical Antipsychotics
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Central Nervous System (CNS) Stimulants
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Tricyclic Antidepressants
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Monoamine Oxidase Inhibitors
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Disorder Type

  • 7.1 Major Depressive Disorder
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Obsessive-Compulsive Disorder
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Generalized Anxiety Disorder
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Panic Disorder
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Drug Type

  • 8.1 Generic Drugs
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Branded Drugs
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Europe
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Asia Pacific
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Middle East and Africa
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Latin America
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porter's Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Otsuka Pharmaceutical
    • 15.3.2 Pfizer
    • 15.3.3 Eli Lilly and Company
    • 15.3.4 AstraZeneca
    • 15.3.5 Novartis
    • 15.3.6 Bristol-Myers Squibb
    • 15.3.7 GlaxoSmithKline
    • 15.3.8 Takeda Pharmaceutical Company
    • 15.3.9 Allergan
    • 15.3.10 Johnson & Johnson
    • 15.3.11 Zhejiang NHU Company Ltd
    • 15.3.12 Sebela Pharmaceuticals